The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial

Young-Rak Cho, Young-Dae Kim, Tae-Ho Park, Kyungil Park, Jong-Sung Park, Heekyung Baek, Sun-Young Choi, Kee-Sik Kim, Taek-Jong Hong, Tae-Hyun Yang, Jin-Yong Hwang, Jong-Seon Park, Seung-Ho Hur, Sang-Gon Lee, Young-Rak Cho, Young-Dae Kim, Tae-Ho Park, Kyungil Park, Jong-Sung Park, Heekyung Baek, Sun-Young Choi, Kee-Sik Kim, Taek-Jong Hong, Tae-Hyun Yang, Jin-Yong Hwang, Jong-Seon Park, Seung-Ho Hur, Sang-Gon Lee

Abstract

Background: Angiotensin-converting enzyme inhibitors and the angiotensin-receptor blocker valsartan ameliorate ventricular remodeling after myocardial infarction (MI). Based on previous clinical trials, a maximum clinical dose is recommended in practical guidelines. Yet, has not been clearly demonstrated whether the recommended dose is more efficacious compared to the lower dose that is commonly used in clinical practice.

Method/design: Valsartan in post-MI remodeling (VALID) is a randomized, open-label, single-blinded multicenter study designed to compare the efficacy of different clinical dose of valsartan on the post-MI ventricular remodeling. This study also aims to assess neurohormone change and clinical parameters of patients during the post-infarct period. A total of 1116 patients with left ventricular dysfunction following the first episode of acute ST-elevation MI are to be enrolled and randomized to a maximal tolerable dose (up to 320 mg/day) or usual dose (80 mg/day) of valsartan for 12 months in 2:1 ratio. Echocardiographic analysis for quantifying post-MI ventricular remodeling is to be conducted in central core laboratory. Clinical assessment and laboratory test are performed at fixed times.

Discussion: VALID is a multicenter collaborative study to evaluate the impact of dose of valsartan on the post-MI ventricular remodeling. The results of the study provide information about optimal dosing of the drug in the management of patients after MI. The results will be available by 2012.

Trial registration: NCT01340326.

Figures

Figure 1
Figure 1
Overall study algorithm of the VALID study. This figure illustrates the study algorithm. A total of 1116 patients will be randomly allocated into the usual dose group (n = 372) and high dose group (n = 744) and followed-up for 12 months after discharge.
Figure 2
Figure 2
Titration scheme of study drug. In the usual dose group, valsartan 40 mg twice a day is administrated throughout the study period. For those in the high dose group, dose is up-titrated to 80 mg twice a day before hospital discharge and finally to 160 mg twice a day after 2 weeks during outpatient visits.

References

    1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observation and clinical implications. Circulation. 1990;81:1161–1172. doi: 10.1161/01.CIR.81.4.1161.
    1. Gaudron P, Ellis C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors. Circulation. 1993;87:755–763.
    1. St John Sutton M, Pfeffer MA, Plapoert T. for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictor of adverse cardiovascular events after myocardial infarction. Circulation. 1994;89:68–75.
    1. Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarction size and ventricular function in rats. Circ Res. 1979;44:503–512.
    1. Hammerman H, Kloner RA, Alker KJ, Schoen FJ, Braunwald E. Effect of transient increased afterload during experimentally induced acute myocardial infarction in dogs. Am J Cardiol. 1985;55:566–570. doi: 10.1016/0002-9149(85)90248-6.
    1. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AE, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Eng J Med. 1988;11:12–19.
    1. Noda K, Sasaguri M, Ishida M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovas Res. 1993;27:334–340. doi: 10.1093/cvr/27.2.334.
    1. Giannuzzi P, Temporelli PG, Bosimini E Gentile F, Lucci D, Maggioni AP, Tavazzi L, Badano L, Stoian I, Piazza R, Heyman I, Levantesi G, Cervesato E, Geraci E, Nicolosi GL. Heterogeneity of left ventricular remodeling after acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenze nell'Infarto Miocardico-3 Echo substudy. Am Heart J. 2001;141:131–138. doi: 10.1067/mhj.2001.111260.
    1. Pfeffer MA, Braunwald E, Moye LA. on the behalf of the SAVE Investigators. Effect of captopril of mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:685–691.
    1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821–828.
    1. Kober L, Torp-Pederson C, Carlsen E, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandopril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;233:1670–1676.
    1. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edward S, Zelenkofske S, Sellers MA, Califf RM. For the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 2003;349:1893–1906. doi: 10.1056/NEJMoa032292.
    1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235. doi: 10.1161/CIRCULATIONAHA.105.167586.
    1. Krum H. The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005) Eur Heart J. 2005;26:1115–1140.
    1. Francis GS, Cohn JN, Jonson G Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin acitivity, and congestive heart failure. Relation to survival and the effect of therapy in V-HeFT II. The V-HeFT VA Cooperative Study Group. Circulation. 1993;87(6 Suppl):VI40–VI48.
    1. Yang Y, Zhang P, Song L Ruan Y, Xu X, Li Y, Zhou Y, Tian Y, Xu Y, Chen Z. Comparision of the doses of enalapril in preventing left ventricular remodeling after acute myocardial infarction in the rat. China Med J. 2002;115:347–351.
    1. Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica W, Khrakovskaya M, Arnold MO, Schwarz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril or both after myocardial infarction. Circulation. 2005;111:3411–3419. doi: 10.1161/CIRCULATIONAHA.104.508093.
    1. Wong M, Staszewsky L, Latini R, Bariera S, Volpi A, Chiang YT, Benza RL, Gottlieb SO, Kleemann TD, Rosconi F, Vandervoort PM, Cohn JN. Val-HeFT Heart Failure Trial Investigators. Valsartan benefits left venricular structure and function in heart failure; Val-Heft echocardiographic study. J Am Coll Cardiol. 2002;40:970–974. doi: 10.1016/S0735-1097(02)02063-6.
    1. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Lyden L, Thygesen K, Uretsky BF. Comparative effect of low and high doses of the angiotension-converting enzyme inhibitor, lisinopril, on mortality and morbidity in chronic heart failure. Circulation. 1999;100:2312–2318.
    1. Clement DL, De Buyzere M, Tomas M, Vanavermaete G. Long-term effects of clinical outcome with low and high dose in the Captopril in Heart Insufficient Patients Study (CHIPS) Acta Cardiol. 2000;55:1–7. doi: 10.2143/AC.55.1.2005711.
    1. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J. 1998;19:481–489.
    1. HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet. 2009;374:1840–1848. doi: 10.1016/S0140-6736(09)61913-9.
    1. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431–1439. doi: 10.1016/S0140-6736(07)60669-2.
    1. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675. doi: 10.1056/NEJMoa010713.
    1. Lang RM, Bierig M, Devereux RB, flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. American Society of Echocardiography's Guidelines and Standards Committee: European Association of Echocardiography. J Am Soc Echocardiogr. 2005;18:1440–1463. doi: 10.1016/j.echo.2005.10.005.
    1. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis. 9. Boston, Little Brown; 1994.
    1. Nicolosi GL, Latini R, Marino P, Maggioni AP, Barlera S, Franzosi MG, Geraci E, Santoro L, Tavazzi L, Toqnoni G, Vecchio C, Volpi A. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurenets and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial. Eur Heart J. 1996;17:1646–1656.
    1. Lee KH, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ, Choi DH, Cho MC, Kim CJ, Seung KB, Chung WS, Jang YS, Cho JG, Park SJ. Sex differences of the clinical characteristics and early management in the Korea Acute Myocardial Infarction Registry. Korean Circulation J. 2007;37:64–71. doi: 10.4070/kcj.2007.37.2.64.
    1. The PREAMI Investigators. Effect of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome. Results of the Randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med. 2006;166:659–666.
    1. Moon HK, Kim YD, Yang DG, Kim SG, Cha KS, Kim MH, Kim JS, Cha TJ, Joo SJ, Lee JW, Hong TJ, Shin YW, Kim DI, Kim DS, Park JS, Shin DG, Kim YJ. Age and Gender Distribution of patients with acute myocardial infarction admitted to university hospitals during the period of 1990-1999. Korean Circulaiton J. 2003;33:92–96.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren